Sanofi temporarily stopped recruiting Covid-19 patients for hydroxychloroquine trials and they will no longer supply the anti-
malaria drug to treat Covid-19.
These come after the World Health Organization paused its large trial of hydroxychloroquine.
Sanofi is conducting two randomised, controlled clinical trials of hydroxychloroquine for Covid-19. The first was expected when 210
patients in several countries like USA, France, Belgium, and the Netherlands were not in hospital and also suffering from these
disease.
The WHO’s concerned this after the British journal The Lancet published that, many patients are getting high dose and dyeing, death
rates got increased after that.
Sanofi is a French multinational pharmaceutical company headquartered in Paris, France.
